Wall Street expects a year-over-year decline in earnings on higher revenues when Qiagen (QGEN) reports results for the quarter ended December 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on February 4, might help the stock move higher if these key numbers are better than expectations ...

Group 1 - The article does not provide any specific insights or analysis related to companies or industries, focusing instead on the author's credentials and disclosures [1][2][3]

German life sciences tools company Qiagen N.V. (NYSE:QGEN) is reportedly reviewing strategic options, including a potential sale, as renewed takeover interest emerges.The European molecular diagnostics company has engaged advisers while its supervisory board evaluates early-stage approaches from potential suitors, Bloomberg reported on Tuesday, signaling a possible shift after several failed attempts to strike a deal in recent years.Citing people with knowledge of the discussions, the report highlighted tha ...

Qiagen (QGEN) shares soared 16.6% in the last trading session to close at $55.45. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 1.9% loss over the past four weeks.QIAGEN scored a strong price increase on investors’ optimism surrounding its impending 2025 fourth-quarter financial results, which is slated to release on February 4 after the closing bell. The Zacks Consensus Estimate for the fourth quarter revenue suggests a growth ...

We recently published 10 Stocks Breaking Records While Wall Street Bleeds. Qiagen NV (NYSE:QGEN) was one of the top performers on Tuesday. Qiagen soared to a four-year high on Tuesday, as investors loaded portfolios ahead of the results of its earnings performance in the full year and fourth quarter of 2025. At intra-day trading, the stock jumped to its highest price of $57.81 before trimming a few cents to end the day just up by 16.57 percent at $55.45 apiece. A Qiagen employee. Photo from Qiagen webs ...

Qiagen is weighing strategic options, including a potential sale of the diagnostics firm amid fresh takeover interest, Bloomberg News reported on Tuesday, citing people with knowledge of the matter. ...

Company Overview - QIAGEN N.V. is a Netherlands-based holding company and a global leader in Sample to Insight solutions, enabling customers to extract and analyze molecular information from biological samples [3] - The company provides technologies for isolating and processing DNA, RNA, and proteins, as well as assay technologies for analysis and bioinformatics for data interpretation [3] - QIAGEN serves over 500,000 customers worldwide in Life Sciences and Molecular Diagnostics, employing approximately 5,700 people across more than 35 locations as of September 30, 2025 [3] Financial Announcement - QIAGEN plans to release its results for the fourth quarter of 2025 on February 4, 2026, shortly after 22:05 Frankfurt time [1] - A conference call will be held on February 5, 2026, at 15:30 Frankfurt time to discuss the results [1] Conference Call Details - Participants can join the conference call via three options: registering for a call back connection, dialing in by phone, or accessing the audio webcast [2] - Dial-in numbers include U.S.: +1 646 769 9200, UK: +44 (0)20 7769 6464, and Germany: +49 (0)69 254 99300, with a conference ID of 3382302 [2]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Insights - QIAGEN is committed to delivering growth and profitability while investing in product development to enhance performance [3] Company Overview - QIAGEN has been focused on molecular solutions for 40 years, including PCR, digital PCR, and next-generation sequencing for a global customer base [4] - The company typically does not disclose earnings for Q4 or the full year at the JPMorgan Healthcare Conference, but there is a positive sentiment regarding Q4 and full year 2025 performance [3]

Core Insights - QIAGEN is committed to delivering growth and profitability while investing in product development to enhance performance [3] - The company has a history of 40 years in developing molecular solutions, including PCR, digital PCR, and next-generation sequencing [4] Company Performance - QIAGEN typically does not disclose earnings for Q4 or the full year at the JPMorgan Healthcare Conference, but there is an optimistic outlook for Q4 and full year 2025 [3]